SLC25A1 and astrocytoma (excluding glioblastoma): MAP2 expression in human glioma reveals different immunolabeling patterns between oligodendroglioma (i.e., sparse processes, that in our study corresponds to lack of CtP immunolabeling and prominent PNc and Ct immunolabeling) and astrocytoma (i.e., densely ramified astrocytic elements, that correspond to predominately CtP staining in majority of the canine astrocytoma in this study) (37).